Forte Biosciences (FBRX) Non-Current Assets (2016 - 2026)
Forte Biosciences (FBRX) posted quarterly Non-Current Assets of $2.1 million for Q1 2026, up 601.99% year-over-year from $301000.0 in Q1 2025, and down 3.52% quarter-over-quarter from $2.2 million in Q4 2025.
Forte Biosciences (FBRX) Non-Current Assets (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has reported Non-Current Assets for 11 consecutive years, with $2.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets rose 601.99% year-over-year to $2.1 million; the TTM figure through Mar 2026 stood at $6.1 million (up 429.46% YoY), while the FY2025 annual figure was $2.2 million, up 918.6% from the prior year.
- Non-Current Assets fell to $2.1 million in Q1 2026 per FBRX's latest filing, from $2.2 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $2.2 million in Q4 2025 and bottomed at $167000.0 in Q2 2025.
- Historically, Non-Current Assets has averaged $759647.1 across 5 years, with a median of $515000.0 in 2024.
- Annual changes were most pronounced in 2024 — Non-Current Assets slumped 67.08% — and 2025, when it soared 918.6%.
- Forte Biosciences' Non-Current Assets stood at $486000.0 in 2022, then jumped by 34.36% to $653000.0 in 2023, then plunged by 67.08% to $215000.0 in 2024, then jumped by 918.6% to $2.2 million in 2025, then slipped by 3.52% to $2.1 million in 2026.
- Business Quant data shows FBRX's Non-Current Assets at $2.1 million in Q1 2026, $2.2 million in Q4 2025, and $1.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Forte Biosciences | 1.63 Bn | 1.28 Bn | - | 2.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.64 Mn |
| Mar 31, 2026 | 2.11 Mn |
| Dec 31, 2025 | 2.19 Mn |
| Sep 30, 2025 | 1.68 Mn |
| Jun 30, 2025 | 167,000.00 |
| Mar 31, 2025 | 301,000.00 |
| Dec 31, 2024 | 215,000.00 |
| Sep 30, 2024 | 278,000.00 |
| Jun 30, 2024 | 367,000.00 |
| Mar 31, 2024 | 515,000.00 |
| Dec 31, 2023 | 653,000.00 |
| Sep 30, 2023 | 777,000.00 |
| Jun 30, 2023 | 437,000.00 |
| Mar 31, 2023 | 437,000.00 |
| Dec 31, 2022 | 486,000.00 |
| Sep 30, 2022 | 534,000.00 |
| Jun 30, 2022 | 874,000.00 |
| Mar 31, 2022 | 893,000.00 |
| Dec 31, 2021 | 786,000.00 |
| Sep 30, 2021 | 834,000.00 |